XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment, Geographic and Other Revenue Information - Narrative (Detail)
treatmentCourse in Millions, $ in Millions
2 Months Ended 3 Months Ended 6 Months Ended
Feb. 29, 2024
treatmentCourse
Jun. 30, 2024
USD ($)
treatmentCourse
Mar. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
treatmentCourse
operatingSegment
Jul. 02, 2023
Dec. 31, 2023
USD ($)
treatmentCourse
Segment Reporting Information [Line Items]            
Number of segments | operatingSegment       3    
Total assets   $ 216,193   $ 216,193   $ 226,501
Deferred revenues, current   2,528   2,528   2,700
Comirnaty [Member]            
Segment Reporting Information [Line Items]            
Remaining performance obligation   $ 6,000   6,000    
Paxlovid [Member]            
Segment Reporting Information [Line Items]            
Reversal of revenue           $ 3,500
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatmentCourse           6.5
Favorable adjustment for government emergency use authorization inventory returned to the company during the period     $ 771 $ 771    
Government emergency use authorization inventory returned to the company during the period, number of treatment courses | treatmentCourse 5.1          
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]            
Segment Reporting Information [Line Items]            
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse   1.0   1.0    
Paxlovid, NDA-Labeled [Member]            
Segment Reporting Information [Line Items]            
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse   6.1   6.1    
Paxlovid            
Segment Reporting Information [Line Items]            
Remaining performance obligation   $ 2,000   $ 2,000    
Government and Government Sponsored [Member] | Paxlovid and Comirnaty            
Segment Reporting Information [Line Items]            
Deferred revenues   4,300   4,300   $ 5,100
Deferred revenues, current   2,500   2,500   2,600
Deferred revenues, noncurrent   1,800   1,800   $ 2,500
Deferred revenue recognized   $ 200   $ 1,200    
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | US Government [Member]            
Segment Reporting Information [Line Items]            
Concentration risk       7.00% 9.00%